Daré Bioscience to Participate in Upcoming Virtual Conferences
Daré Bioscience announced that CEO Sabrina Martucci Johnson will participate in two virtual conferences: the M Vest and Maxim Group Inaugural Emerging Growth Virtual Conference on March 17-18, 2021, with presentations available on-demand, and BIO-Europe Spring Digital from March 22-25, 2021. Following the M Vest conference, a webcast will be accessible for two weeks via the company's investor relations website.
Daré focuses on innovative women's health products, including unique therapies for contraception and sexual health.
- None.
- None.
SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will participate in the following upcoming virtual conferences:
M Vest and Maxim Group Inaugural Emerging Growth Virtual Conference
March 17-18, 2021
Presentation available on-demand for event participants beginning Wednesday, March 17
You may learn more about the event and register HERE.
BIO-Europe Spring Digital
March 22-25, 2021
You may learn more about the event and register HERE.
A webcast of the company’s presentation at the M Vest and Maxim Group virtual conference will be available following the conference for two weeks under “Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.darebioscience.com.
About Daré Bioscience
Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health, and fertility.
Daré’s product portfolio includes potential first-in-category candidates in clinical development: Ovaprene®, a hormone-free, monthly contraceptive intravaginal ring whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream,
Daré may announce material information about its finances, product candidates, clinical trials and other matters using the Investors section of its website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company, and may also use social media to communicate important information about the company, its finances, product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts in the Investors section of its website and to follow these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted on the investor relations page of Daré’s website mentioned above.
Contact:
Investors on behalf of Daré Bioscience, Inc.:
Tom Masterson
Allele Capital Partners
tmasterson@allelecapital.com
646.573.3216
Source: Daré Bioscience, Inc.
FAQ
What are the upcoming conferences for Daré Bioscience (DARE) in March 2021?
Where can I find the webcast for Daré Bioscience's conference presentation?
What is Daré Bioscience's focus in women's health?
Who is the CEO of Daré Bioscience (DARE)?
How does Daré Bioscience communicate with investors?
